抗血栓治疗心力衰竭的鼻节律 - 一个简短的评论
Rakshya Sharma1,2, Ananta Subedi1,2
1University of South Dakota Sanford School of Medicine.
概括
抗血栓治疗心力衰竭 (HF) 患者的鼻节律并没有显著减少缺血事件或死亡. 虽然抗凝血剂可能会降低中风风险,但它们会增加出血,因此在没有其他迹象的情况下,不建议在HF治疗中常规使用.
科学领域:
- 心脏病学 心脏病学
- 血栓形成的管理
- 临床研究 临床研究
背景情况:
- 心力衰竭 (HF) 是一种普遍的疾病,与严重的发病率和死亡率有关.
- 高血压增加了血栓栓塞事件的风险,包括中风和缺血性心脏病.
- 抗血栓治疗正在探索HF患者的鼻节律,但它的有效性是有争议的.
研究的目的:
- 审查有关抗血栓治疗在心力衰竭患者与鼻节律的有效性现有的文献.
- 评估使用抗血栓剂来管理该患者群体中血栓栓塞风险的证据.
主要方法:
- 随机对照试验 (RCT) 的系统综述,调查高血压患者的抗血栓剂.
- 分析有关中风风险,出血事件,缺血事件和死亡率的数据.
主要成果:
- 在患有鼻节律的HF患者中,抗凝剂 (例如华法林) 的使用表明中风风险降低.
- 然而,抗凝剂治疗与增加出血风险有关.
- 总的来说,抗凝剂治疗在减少总缺血事件或死亡率方面没有显著的益处.
结论:
- 目前的证据不支持在心力衰竭患者中常规使用抗血栓治疗,除非存在其他迹象.
- 降低中风风险和增加出血风险之间的平衡需要仔细考虑.
- 可能需要进一步的研究来确定可能受益于抗血栓治疗的特定亚组.
更多相关视频
相关概念视频
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias
208
Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
208
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
418
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
418
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inotropic Agents
563
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
563
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486


